HANSA BIOPHARMA

Conference Call Presentation Jan-Mar 2020

Lund, April 28, 2020

Forward-looking statement

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

EMA process on track; CHMP opinion expected in the second quarter 2020

Highlights for the first quarter 2020

- Imlifidase in kidney transplantation
  - Formal adoption of outstanding questions expected in April; CHMP opinion expected in the second quarter 2020
  - Discussions with the FDA on the design of a new trial in kidney transplantation in the US is progressing according to plan
  - Long-term follow-up data demonstrate two-year graft survival of 89% after imlifidase treatment and transplantation
- Progress in our pipeline
  - Anti-GBM study fully enrolled; Completion marks an important milestone for the Company outside transplantation
  - Four patients have been treated in GBS and AMR respectively.
- COVID-19 pandemic may impact parts of the business
  - Recruitment in AMR and GBS expected to be delayed 3-6 months
  - Initiation of US imlifidase trial
  - Potential European launch of imlifidase in kidney transplantation
  - Financing strategy
- Cash position stood at SEK 477m (~USD 47m) end of March; Hansa Biopharma is financed through mid 2021

EMA: Formal adoption of outstanding questions expected at April meeting. CHMP Opinion expected in Q2 2020

EU: Imlifidase in kidney transplantation

Europe (EMA review)

- Regulatory review process progressing as expected. Day 180 responses submitted end of Q1 2020
- Good dialogue with EMA; expect formal adoption of list of outstanding questions at the April CHMP session
- CHMP Opinion expected at subsequent CHMP meeting in Q2
- Decision by European Commission expected in Q3 2020

Launch strategy

- Our launch strategy involves targeting of leading kidney transplantation centers with the potential to become early adopters and centers of reference
- COVID-19 impact: Our potential launch may be affected by the pandemic, incl. limited access to market access authorities, potentially delaying pricing and reimbursement
- It remains, however, our aim to launch imlifidase this year



FDA: Discussions around new US trial design progressing as planned; New study planned to be initiated in Q4

US: Imlifidase in kidney transplantation

U.S. (FDA)

- Discussions with the FDA on the design of a new US trial in kidney transplantation is progressing according to plan. Submission of the study protocol is expected in Q2 2020
- The new trial is expected to include ~50 patients with a cPRA score of 99.9% or above. eGFR (kidney function) will be used as a surrogate endpoint to demonstrate a clinical benefit of imlifidase therapy vs. patients being waitlisted
- COVID-19 impact: Potential reprioritization of activities by the FDA may impact the timeline for the initiation of our new US trial
- It remains our aim to start recruitment in Q4 2020 following receipt of the necessary ethical approvals and setting up of trial centers in the US

HANSA BIOPHARMA

Enrollment in Anti-GBM completed; Four patients recruited in each of the AMR and GBS studies

Ongoing Phase 2 studies

Enrollment status end Q1'2020

Anti-GBM (investigator-initiated study)

- 15/15 patients enrolled in anti-GBM across 5 European countries
- First data read-out expected in Q3 2020

Antibody Mediated Rejection

- 4/30 patients enrolled in AMR study.
- COVID-19 expected to delay the recruitment of AMR patients by 3-6 months. Enrollment is now expected to be completed H1 2021

Guillain-Barré Syndrome

- 4/30 patients enrolled
- COVID-19 expected to delay the recruitment of GBS patients by 3-6 months. Enrollment is now expected to be completed in H2 2021

▪ Patients enrolled
▪ Patients left

Broad pipeline in transplantation and auto-immune diseases

Candidate / Project	Indication	Research/ Preclinical	Phase 1	Potentially Pivotal/ Phase 2	Phase 3	Marketing Authorization	Marketed	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients [1,2]					*)		CHMP Opinion Q2 2020
	US: Kidney transplantation in highly sensitized patients [1,2]				**)			Finalization of study design Q2 2020 / first patient dosed Q4 2020
	Anti-GBM antibody disease							Data read-out Q3 2020
	Antibody mediated kidney transplant rejection (AMR)							Complete enrolment of 30 patients
	Guillain-Barré syndrome (GBS)							Complete enrolment of 30 patients
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology							Development of CMC process / Tox studies
EnzE	Cancer immunotherapy							Research phase

Completed Ongoing

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7).

[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine).

*) EMA: In imlifidase for kidney transplantation we have filed for conditional approval after completion of phase 2. A post-approval study would need to be executed in case of approval.

**) FDA: Agreement with the FDA on a regulatory path forward in the US. New clinical study could support BLA submission by 2023

HANSA BIOPHARMA

Investments in SG&A and R&D increased in preparation for potential conditional approval in EU and due to pipeline advancement

SG&A expenses (Q/Q)



R&D expenses (Q/Q)



Net loss (Q/Q)



SG&A expenses (Y/Y)



R&D expenses (Y/Y)



Net loss (Y/Y)



Cash position stood at SEK 477m (~USD 47m) end of Q1 2020; Hansa Biopharma is financed through mid 2021

Operating cash flow (Q/Q)



Cash & short term investments (Q/Q)



Number of employees (Q/Q)



Operating cash flow (Y/Y)



Shareholders equity (Q/Q)



* Excl. positive impact from sale of Genovis shares of SEK 89m in Q2'19

Upcoming milestones



* Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund

** An expected delay in the recruitment of patients of 3-6 months in the AMR and GBS studies have been incorporated following COVID-19 (Corona)

HANSA BIOPHARMA

Q&A

Visit our web site
www.hansabiopharma.com

… at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives…